Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Lir Life Sciences finishes animal study testing needle-free patches for obesity drugs, aiming to improve treatment access and adherence.
Lir Life Sciences has completed designing a comparative animal study to test its transdermal delivery platform, using cell-penetrating peptides to enable needle-free administration of GLP/GIP-based obesity therapies.
The study, conducted with scientific partners, will evaluate how effectively transdermal formulations control blood glucose after an oral challenge, comparing them to standard subcutaneous injections.
It aims to identify which GLP/GIP therapies perform best with the patch technology, guiding future development, formulation optimization, and Investigational New Drug (IND) planning.
The company’s goal is to create affordable, patient-friendly alternatives to injectable treatments, improving adherence and access to metabolic disease therapies.
Results are expected to inform clinical strategy and support broader efforts to expand treatment options through innovative delivery methods.
Lir Life Sciences finaliza el estudio en animales probando parches sin aguja para medicamentos contra la obesidad, con el objetivo de mejorar el acceso y la adherencia al tratamiento.